Better Buy in 2026: Pfizer or Eli Lilly?

Eli Lilly has been the clear growth leader driven by GLP-1 drugs (Mounjaro, Zepbound) and expects roughly $63 billion in sales this year (up ~40% from $45 billion in 2024) with ~31% profit margins, while investing $6 billion in a U.S. plant to expand production. Pfizer faces declining COVID-era sales, expects roughly $62 billion in revenue this year (versus $63.6 billion last year) and 2026 guidance of $59.5–$62.5 billion with ~16% margins, but has pursued acquisitions (Seagen ~$43B, Metsera ~$7B) to rebuild growth. Valuation spreads are wide (Lilly P/E ~52 vs Pfizer P/E ~15), and the analyst favors Pfizer as a value play given downside already priced in despite Lilly's stronger fundamentals.

Analysis

Market structure: GLP‑1 winners (LLY, Novo Nordisk peers) retain pricing power short‑to‑medium term as demand outstrips immediate manufacturing uplift; LLY’s $6B Alabama capex and 40% revenue growth guidance to ~$63B for 2025 imply continued share gains and margin expansion (31% margin). Pfizer (PFE) is a laggard operationally — Seagen ($43B) and Metsera ($7B) give optionality into oncology/obesity but integration and trial risk mean market assigns a ~15 P/E discount versus LLY’s ~52.

Risks: Tail risks include GLP‑1 regulatory/coverage clampdowns or safety signals (30–60 day headline risk) that could halve demand, plus Seagen integration setbacks or trial failures for Metsera (6–24 months). Operational supply risks shrink as LLY onshores production (reduces tariff/exposure); Pfizer faces execution risk and potential cash burn if acquisitions underperform.

Trade implications: Near term (days–weeks) expect LLY to remain bid; implied vols likely rich into earnings — monetize via income strategies. Medium term (3–12 months) PFE offers asymmetric value: low P/E with clear binary catalysts (Seagen synergy disclosures, Metsera readouts). Use pair trades to express valuation dispersion while hedging macro beta.

Contrarian angle: Consensus underestimates execution drag on large M&A at PFE and overestimates permanence of LLY’s premium multiple — a 20–30% pullback in LLY on policy/coverage shifts is plausible, creating re‑entry. Conversely, a clean Seagen integration or positive Metsera Phase II within 12 months could re‑rate PFE by 25–40%, so asymmetric, option‑structured exposure is preferred.

Key Decisions for Investors

• Establish a 3% portfolio long position in PFE over next 30 days with 12–24 month horizon; hedge tail risk with a 12‑month protective put at ~15% OTM sized to cover 50% of position notional. Rationale: low 15 P/E vs peers and binary upside from Seagen/Metsera integration.
• Avoid initiating fresh full‑weight longs in LLY; if already long, trim 25–40% and sell 6–9 month covered calls ~20% OTM to crystallize gains and capture rich implied volatility ahead of upcoming earnings/readouts. If downside protected, buy 9–12 month puts 10–15% OTM for asymmetric protection against GLP‑1 policy shocks.
• Implement a relative trade: long PFE 2% / short LLY 1% (dollar‑neutralish) for 6–12 months to capture mean reversion of valuation gap; rebalance if either leg moves >10% or if LLY margin guidance surprises >+/-500 bps.
• Use options to express asymmetric upside: buy a 12‑month PFE call spread (30–45% OTM long, 60% OTM short) sized to 1% portfolio delta and finance ~50–70% of cost by selling LLY 6–9 month call spreads 20–30% OTM. Monitor FDA/CMS GLP‑1 and Seagen integration updates in the next 90 days as explicit triggers to adjust.